Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis and HIV news

Show

From To
European Commission Grants Marketing Authorizations for AbbVie's VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) for the Treatment of Chronic Hepatitis C

The treatment has been approved with or without ribavirin (RBV) for patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection, including those with compensated liver cirrhosis, HIV-1 co-infection, patients on opioid substitution therapy and liver transplant recipients.1,2 Additionally, VIEKIRAX has been approved for use with RBV in genotype 4 (GT4) chronic hepatitis C patients.

Published
16 January 2015
From
AbbVie press release
NICE plans to support device for diagnosing liver damage without surgery

NICE is consulting on draft guidance on a device that aims to diagnose and monitor liver damage, without the need for surgery. The provisional recommendations support using the device, Virtual Touch Quantification (VTq), in adults and children with chronic hepatitis B or C who need assessment of liver fibrosis.

Published
15 January 2015
From
NICE
How Much Could AbbVie Inc. Make Selling Its Hepatitis C Drug This Year?

AbbVie has issued its guidance for 2015, and that guidance suggests that its newly launched hepatitis C drug cocktail, Viekira Pak, could be a big driver of earnings growth this year. In December, Viekira Pak received FDA approval as a treatment for hepatitis C genotype 1 after delivering compelling functional cure rates in the mid-90% range during clinical trials. That approval was highly anticipated by health care payers desperate for competition in this market, because hepatitis C market share leader Gilead Sciences' two hepatitis C drugs, Sovaldi and Harvoni, carry eye-popping price tags that are translating into billions of additional dollars in health care spending.

Published
15 January 2015
From
The Motley Fool
India rejects Gilead's Hepatitis C drug patent request

India's patent office has rejected an application from U.S.-based Gilead Sciences Inc for its hepatitis C drug Sovaldi, paving the way for local drugmakers to launch cheaper generic versions of the $1,000-a-pill medicine.

Published
14 January 2015
From
Reuters
Doctors Question Wider Hepatitis C Screening Despite Cures

Doctors should resist the urge to screen a wider group of patients for hepatitis C, a group of physicians said today in the British Medical Journal, despite the introduction of new drugs that can cure the liver disease. Expanded screening would flag the disease in people who are unlikely to die from it, leading to unnecessary treatment that may itself be harmful, said the group, including Kenneth Lin, an associate professor at Georgetown University School of Medicine.

Published
14 January 2015
From
Bloomberg
US: Prime Therapeutics breaks from competition, strikes deals to prefer both Harvoni, Viekira hepatitis C drugs

The agreements place both Gilead’s Harvoni® and AbbVie’s Viekira Pak® on Prime’s preferred drug list (formulary), meaning members can more easily get the medicine they need to feel better and live well.

Published
13 January 2015
From
Prime Therapeutics press release
Merck speeds up drug-submission plans for hep C, lung cancer

Merck said it planned to file an application with the FDA in the first half of the year for marketing approval for grazoprevir/elbasvir, a new two-drug, single-pill combination to treat hepatitis C.

Published
13 January 2015
From
Reuters
HCV prevention campaigns need to focus on reducing frequency of injecting drug use involving sharing of equipment

Sharing injecting equipment is associated with a low per-event probability of hepatitis C virus (HCV) transmission, Australian investigators report in the online journal PLOS ONE. Their analysis

Published
13 January 2015
By
Michael Carter
Spaniards rally over hepatitis C drugs

Thousands of people, diagnosed with hepatitis C, have rallied in several cities across Spain to urge the government to make it easier for patients with this disease to access the latest-generation medicines.

Published
12 January 2015
From
Press TV
Interferon-free combination therapy prevents recurrence of HCV after liver transplantation

A 24-week course of sofosbuvir and ribavirin can eliminate hepatitis C virus infection in two-thirds of patients who undergo liver transplantation, with positive consequences on their short- and long-term prognoses, according to two new studies published in Gastroenterology, the official journal of the American Gastroenterological Association.

Published
09 January 2015
From
Eurekalert Inf Dis

Filter by country